Agios Pharmaceuticals, Inc. (AGIO) Stock Forecast
Data as of Jun 16, 2026Healthcare · Current price $32.25 (+1.41%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 12, 2026 | Greg Renza | Truist Financial | $39.00 | +20.9% |
| Dec 24, 2025 | Gregory Renza | Truist Financial | $38.00 | +17.8% |
| Oct 20, 2025 | Emily Bodnar | H.C. Wainwright | $56.00 | +73.6% |
| May 2, 2025 | Greg Harrison | Scotiabank | $71.00 | +120.2% |
| Oct 31, 2024 | Danielle Brill | Raymond James | $51.00 | +58.1% |
| Sep 27, 2024 | Andrew Berens | Leerink Partners | $56.00 | +73.6% |
| Sep 10, 2024 | Chris Raymond | Raymond James | $56.00 | +73.6% |
| Jun 17, 2024 | Chris Raymond | Raymond James | $55.00 | +70.5% |
| Jun 3, 2024 | Gregory Renza | RBC Capital | $53.00 | +64.3% |
| May 28, 2024 | Chris Raymond | Raymond James | $45.00 | +39.5% |
| Apr 30, 2021 | Peter Lawson | Barclays | $70.00 | +117.1% |
Top Analysts Covering AGIO
AGIO vs Sector & Market
| Metric | AGIO | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.29 | 2.24 | 2.40 |
| Analyst Count | 14 | 8 | 19 |
| Target Upside | +42.1% | +11475.0% | +17.1% |
| P/E Ratio | -3.51 | 3.91 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $16M | $19M | $23M | 7 |
| 2026-09-30 | $21M | $25M | $32M | 4 |
| 2026-12-31 | $27M | $33M | $41M | 4 |
| 2027-12-31 | $159M | $240M | $304M | 8 |
| 2028-12-31 | $374M | $374M | $374M | 8 |
| 2029-12-31 | $325M | $489M | $643M | 7 |
| 2030-12-31 | $424M | $639M | $841M | 7 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $-1.90 | $-1.70 | $-1.63 | 7 |
| 2026-09-30 | $-2.07 | $-1.58 | $-1.18 | 3 |
| 2026-12-31 | $-1.94 | $-1.47 | $-1.11 | 3 |
| 2027-12-31 | $-6.39 | $-5.12 | $-3.98 | 9 |
| 2028-12-31 | $-5.01 | $-3.58 | $-2.25 | 8 |
| 2029-12-31 | $-3.37 | $-2.39 | $-1.34 | 6 |
| 2030-12-31 | $-0.23 | $-0.17 | $-0.09 | 6 |
Frequently Asked Questions
What is the analyst consensus for AGIO?
The consensus among 14 analysts covering Agios Pharmaceuticals, Inc. (AGIO) is Buy with an average price target of $37.75.
What is the highest price target for AGIO?
The highest price target for AGIO is $71.00, set by Greg Harrison at Scotiabank on 2025-05-02.
What is the lowest price target for AGIO?
The lowest price target for AGIO is $38.00, set by Gregory Renza at Truist Financial on 2025-12-24.
How many analysts cover AGIO?
14 analysts have issued ratings for Agios Pharmaceuticals, Inc. in the past 12 months.
Is AGIO a buy or sell right now?
Based on 14 analyst ratings, AGIO has a consensus rating of Buy (2.29/5) with a +42.1% upside to the consensus target of $37.75.
What are the earnings estimates for AGIO?
Analysts estimate AGIO will report EPS of $-1.70 for the period ending 2026-06-30, with revenue estimated at $19M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.